While juvenile arthritis can cause joint damage and limit function, rheumatologists strongly encourage children with JIA to live normal lives.
Patient Fact Sheet: Juvenile Idiopathic Arthritis
Several types of arthritis fall under the JIA heading. This inflammation begins before patients reach the age of 16 years, and may involve one or many joints and cause other symptoms such as fevers, rash, and eye inflammation.
Coding Corner: May’s Coding Challenge
A 54-year-old female with rheumatoid arthritis is seen by the rheumatologist for a follow-up visit.
A Rheumatologic Perspective on Intimacy and Chronic Illness
Sexual dysfunction is frequently one of the first manifestations of physical illness, but is often not inquired about on routine reviews of systems.
Désirée Van Der Heijde, MD, PhD, a Key Driver of Treatment Advances
Dr. van der Heijde learned early in her career that serendipity often plays a role in clinical research and treatment advances.
The Three-Fold Cord of Rheumatology
How the proverbial three-fold cord applies to rheumatology.
American College of Rheumatology (ACR) Research and Education Foundation Brings Researchers Together in Santa Fe
Two recent meetings supported by the ACR Research and Education Foundation (REF) provided investigators in disease-targeted research initiatives the opportunity to present on their progress and build collaborations.
ACR/ARHP Annual Scientific Meeting Plenary Highlights Targets and Treatments for Several Diseases
Promising therapeutic targets for rheumatic diseases were the focus of a plenary session here at the ACR/ARHP 2011 Annual Scientific Meeting in November. Presenters discussed discoveries and treatments for systemic sclerosis, rheumatoid arthritis, vasculitis, and Behçet’s disease.
Rheumatoid Arthritis Drugs May Cut Cardiovascular Risk
Other studies at the ACR/ARHP Annual Scientific Meeting in November examined arthritis treatment, scleroderma screening.
Where Will Kinase Inhibitors Fit into the RA Treatment Mix?
Presenters at “Looking Ahead to Kinase Inhibition in Rheumatoid Arthritis,” a session here at the 2011 ACR/ARHP Annual Scientific Meeting, delved into some of the big questions that rheumatology faces with kinase inhibitor use.
- « Previous Page
- 1
- …
- 61
- 62
- 63
- 64
- 65
- …
- 74
- Next Page »